Salvage Gene Is At The Root Of Many Mutations

August 23, 1996

A trio of University of Rochester researchers has unexpectedly discovered that most mutations in yeast are caused by the activity of an enzyme that acts to salvage irreparably damaged DNA. The enzyme, REV1, helps a cell evade its own stringent quality control and opens the door to mutations. The findings are reported in the August 22 issue of Nature.

The researchers set out to understand the function of a family of DNA repair enzymes in yeast. When they damaged the yeast's DNA and then studied the yeast's coping mechanisms, they made a startling discovery: Almost all mutations in DNA, ironically, result from the activity of one of the DNA repair enzymes, REV1.

"We really found something that we weren't at all looking for," says David Hinkle, associate professor of biology. "This was a bombshell." Also working on the project, funded by the National Institutes of Health, are postdoctoral fellow John Nelson and Christopher Lawrence, professor of biophysics.

The vast majority of mutations come not from asbestos, pesticides, or other environmental factors, but from normal chemistry that goes on within our bodies. "DNA is not a stainless steel molecule," Lawrence points out. "It is susceptible to damage as a natural part of its existence."

The most common form of DNA damage is sporadic loss of individual molecules of adenine and guanine -- two of the four bases that encode genetic information along a strand of DNA. Such losses result in genetic gaps known as "abasic" sites.

"Formation of these abasic sites," says Hinkle, "is, in fact, one of the most common occurrences in our cells," taking place every day in about 10,000 to 20,000 of the three trillion DNA bases in each of our cells. Uncorrected abasic sites can be lethal to cells because they act as vast potholes, halting the polymerase enzymes that usually zip along a strand of DNA during replication. If a cell is unable to replicate its DNA, it will eventually die.

Cells usually avoid this fate -- as well as mutations -- by accurately repairing abasic sites in a variety of ways. But very rarely these cellular efforts at quality control fail, and it's at this desperate stage that REV1, the enzyme discovered by Nelson, Hinkle, and Lawrence, causes a mutagenic bypass to occur.

"REV1, in its efforts to cope with DNA damage, can actually produce mutations," Nelson says. "When exposed to DNA- damaging agents, yeast without the REV1 enzyme develop less than one percent as many mutations as yeast with the enzyme."

In the Nature paper, the Rochester researchers show that REV1 leapfrogs the gap by inserting a default base, cytosine, at the abasic site, allowing the unique zeta DNA polymerase -- recently announced by the same group of scientists in Science -- to resume copying the DNA strand. This saves the cell from certain death, but its survival carries a potentially steep price: The arbitrary placement of a cytosine base may change the genetic code and cause a mutation. While individual mutations are seldom serious, "if you get that rare mutation that causes cancer, you're in trouble," Nelson says.

"There's every reason to believe that mutagenesis in humans will prove to be very similar to that in yeast," says Lawrence, noting that Rochester scientists have already identified similar gene sequences in human DNA. "And mutagenesis is at the heart of cancer, which is thought to occur because mutations permit precancerous cells to overcome the genetic defenses against unlimited cell proliferation and migration."

The Rochester researchers believe the findings could open a major new avenue of cancer prevention. People with genetic predispositions to cancer could be given drugs to knock out the REV1 enzyme, stopping mutations before they arise.

University of Rochester

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to